Tags : MRSA Bacteremia

Regulatory

ContraFect’s Exebacase Receives the US FDA’s Breakthrough Therapy Designation for

Shots: The BTD is based on P-II superiority trial assessing Exebacase + SOC antibiotic therapy vs SOC alone in patients with Staphylococcus aureus bacteremia, including endocarditis In a pre-specified analysis of the subgroup with MRSA infections, the clinical responder rate @day14 (74.1% vs 31.3%). The Exebacase demonstrated a reduction in the 30-day all-cause mortality, 4days […]Read More